GoodRx Holdings
GDRX

$7.71

3.13%

Market Cap: $2.93B

About: GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Employees: 694

Information Technology Computer Processing & Data Preparation

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

24% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 25

20% more call options, than puts

Call options by funds: $6.4M | Put options by funds: $5.33M

11% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 44

11% more capital invested

Capital invested by funds: $924M [Q1] → $1.03B (+$103M) [Q2]

4% more funds holding

Funds holding: 155 [Q1] → 161 (+6) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

0% more ownership

Funds ownership: 139.62% [Q1] → 139.63% (+0%) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8.50

10%

upside

Avg. target

$9.50

23%

upside

High target

$10

30%

upside

4 analyst ratings

2 positive

50%

2 neutral

50%

0 negative

0%

RBC Capital Sean Dodge 55% 1-year accuracy 24 / 44 met price target	30%upside $10	Outperform Reiterated	16 Aug 2024
Citigroup Daniel Grosslight 90% 1-year accuracy 9 / 10 met price target	30%upside $10	Buy Maintained	9 Aug 2024
UBS Eric Sheridan 60% 1-year accuracy 33 / 55 met price target	10%upside $8.50	Neutral Maintained	9 Aug 2024
Morgan Stanley Craig Hettenbach 63% 1-year accuracy 5 / 8 met price target	23%upside $9.50	Equal-Weight Maintained	10 Jun 2024

See Analyst Rankings

Financial journalist opinion

GoodRx to Participate in Upcoming Investor Conferences

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced that executives from the Company will participate in a fireside chat at each of the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Thursday, September 5, 2024 at 7:45 a.m. Eastern Time (4:45 a.m. Pacific Time) Wells Fargo 2024 Healthcare Conference in Boston, MA.

GoodRx to Participate in Upcoming Investor Conferences

GoodRX Subscription Revenue Down 8% but Active User Numbers Are Up

It was a mixed bag of growth and challenges for digital healthcare platform GoodRx during the second quarter. In reporting its second-quarter results Thursday (Aug. 8), GoodRx said monthly active users (MACs) rose 8%, contributing to a 7% rise in prescription transactions revenue, which totaled $146.7 million.

GoodRX Subscription Revenue Down 8% but Active User Numbers Are Up

GoodRx Holdings, Inc. (GDRX) Q2 2024 Earnings Call Transcript

GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Aubrey Reynolds - Director of Investor Relations Scott Wagner - Interim Chief Executive Officer Karsten Voermann - Chief Financial Officer Mike Walsh - President & EVP, Prescription Marketplace Conference Call Participants Charles Rhyee - TD Cowen Lisa Gill - JPMorgan John Ransom - Raymond James Stephanie Davis - Barclays Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Securities Kevin Caliendo - UBS Allen Lutz - Bank of America Daniel Grosslight - Citi Jack Wallace - Guggenheim Securities George Hill - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by, and welcome to the Rx Second Quarter 2024 Earnings Call. As a reminder, today's conference call is being recorded.

GoodRx Holdings, Inc. (GDRX) Q2 2024 Earnings Call Transcript

GoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription Challenges

Prescription savings platform GoodRx Holdings Inc. GDRX reported second-quarter revenue of $200.61 million, up 6% year over year, almost in line with the consensus of $200.4 million.

GoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription Challenges

Zacks Investment Research

GoodRx (GDRX) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

GoodRx (GDRX) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research

GoodRx Holdings, Inc. (GDRX) Misses Q2 Earnings and Revenue Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

GoodRx Holdings, Inc. (GDRX) Misses Q2 Earnings and Revenue Estimates

GoodRx Reports Second Quarter 2024 Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $200.6 million Net income of $6.7 million; Net income margin of 3.3% Adjusted Net Income1 of $32.4 million; Adjusted Net Income Margin1 of 16.1% Adjusted EBITDA1 of $65.4 million; Adjuste.

GoodRx Reports Second Quarter 2024 Results

Zacks Investment Research

Unveiling GoodRx (GDRX) Q2 Outlook: Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for GoodRx (GDRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

Unveiling GoodRx (GDRX) Q2 Outlook: Wall Street Estimates for Key Metrics

GoodRx Q2 Earnings Preview

GoodRx stock rated a sell due to industry headwinds, cost growth outpacing revenue, and needing 12%+ growth to justify price. Q2 earnings expected to be in line with guidance, but long-term guidance doesn't support current price point. Upside potential if GoodRx doubles market growth, but industry headwinds and growth struggles pose challenges.

GoodRx Q2 Earnings Preview

Boehringer-GoodRx partner to offer Humira rival at 92% discount

A close copy version of Abbvie's blockbuster arthritis drug Humira will be available at a 92% discount to its list price on the GoodRx website, the digital healthcare platform and German drugmaker Boehringer Ingelheim said on Thursday.

Boehringer-GoodRx partner to offer Humira rival at 92% discount

See News Rankings